Kenan BARUT, Sezgin ŞAHİN, Amra ADROVIC, Muhammet KÖŞKER, Ömer KILIÇ, Yıldız CAMCIOĞLU, Haluk ÇOKUĞRAŞ, Necla AKÇAKAYA, Betül SÖZERİ, Özgür KASAPÇOPUR

Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy

Background/aim: The aim of this study is to evaluate the effect of biologic drugs on the tuberculin skin test in patients with juvenile idiopathic arthritis. Materials and methods: A total of 234 biologic drug-using juvenile idiopathic arthritis patients and 45 healthy controls were enrolled in the study. The tuberculin skin test results of the patients, which had been routinely provided during follow-up, were obtained from the patient files. Tuberculin skin test values of ≥ 5 mm were considered to be positive. Results: The mean diameter of tuberculin skin test induration was 4.99 ± 6.84 mm (IQR: 0-10 mm) and 7.83 ± 3.47 mm (IQR: 0-16 mm) in patients and controls, respectively (P < 0.05). Tuberculin skin test positivity (≥5 mm) was found in 96 (41%) and 38 (84.4%) of patients and controls, respectively (P < 0.001). There was no induration in 125 (53.4%) patients and 3 (6.6%) healthy controls, respectively (P < 0.001). Conclusion: In the patients with juvenile idiopathic arthritis who were using biologic drugs, tuberculin skin test induration was significantly lower compared to the control group. Tuberculin skin tests alone seem inadequate for recognition of latent tuberculosis in juvenile idiopathic arthritis patients on anti-TNF therapy.

Keywords:

Juvenile idiopathic arthritis, tuberculin test, biologic therapy,

PDF

___

Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile idiopathic arthritis. Balkan Med J 2017; 34: 90-101.
Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep 2015; 17: 66.
Young J, O’Connor ME. Risk factors associated with latent tuberculosis infection in Mexican American children. Pediatrics 2005; 115: e647-653.
Chapman HJ, Lauzardo M. Advances in diagnosis and treatment of latent tuberculosis infection. J Am Board Fam Med 2014; 27: 704-712.
Yıldırım C, Küçük AI, Öngüt G, Önguç D, Çolak D, Mutlu G. Evaluation of tuberculin reactivity in different age groups with and without BCG vaccination. Mikrobiyol Bul 2009; 43: 27-35 (in Turkish with abstract in English).
Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, Pastor C, Harrison J, Sanchez- Schwartz C. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361.
Araujo Z, de Waard JH, de Larrea CF, Borges R, Convit J. The effect of Bacille Calmette-Guerin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis. Vaccine 2008; 26: 5575-5581.
Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, Tastan Y. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 2009; 36: 2029-2032.
Camlar SA, Makay B, Appak O, Appak YC, Esen N, Gunay T, Anal O, Unsal E. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 2011; 30: 1189-1193.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390- 392.
[No authors listed.] Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161: 221-247.
Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012; 32: 2675-2679.
Brunelli JB, Bonfiglioli KR, Silva CA, Kozu KT, Goldenstein- Schainberg C, Bonfa E, Aikawa NE. Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Rev Bras Reumatol 2017; 57: 392-396.
Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011; 29: 790-794.
Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-1173.